Diabetes Pre-work Flashcards
1
Q
Clinical features T2DM - symptoms
A
- Polyuria
- Polydipsia
- Unexplained weight loss
- Recurrent infections
- Tiredness
2
Q
Signs of T2DM
A
- Acanthosis nigricans
- Presence of risk factors?
3
Q
Diagnostic criteria for T2DM
A
- If symptoms, can have 1 hyperglycaemic reading
- If no symptoms, needs repeat test to confirm
4
Q
Values for diabetes diagnosis for readings
A
- HbA1C of 48mmol/mol (6.5%) or more
- Fasting glucose of 7mmol/L or more
- Random blood glucose of 11.1mmol/L or more in presence of signs/symptoms
5
Q
When should HbA1C not be used to confirm diabetes?
A
- Children and young people under 18 - use fasting/random sample
- Pregnant women or 2 months post partum
- Symptoms for less than 2 months
- High risk of diabetes who are acutely unwell
- Taking medication that can cause hyperglycaemia (eg corticosteroids)
- Acute pancreatic damage
- End stage renal disease
- HIV infection
6
Q
When to interpret HbA1C with caution?
A
- Abnormal Hb eg haemoglobinopathy
- Severe anaemia (any cause)
- Altered red cell lifespan (eg splenectomy)
- Recent blood cell transfusion
7
Q
Management T2 diabetes - general
A
- Offer referral to structured education program eg DESMOND
- Provide sources of information - Diabetes UK
- Lifestyle advice - diet, exercise etc
- Assess impact on mood - Diabetes and your emotions patient resource
- Influenza and pnuemococcal vaccine
- Wear or carry some form of Diabetes identification - bracelet, necklace, watch, card, wristband
8
Q
Monitoring for T2DM
A
- Measure HbA1C at 3-6 monthly intervals until stable on unchanging diabetic treatment
- Then every 6 months after stable
- Screening for complications
9
Q
How often is screening for T2DM complications?
A
- Eyes - at diagnosis and every 2 year for those low risk, annually for others
- Diabetic foot check - at diagnosis and then once per year, more frequent if higher risk
- Kidney - annual UACR (early morning sample) and eGFR
- CVD risk assessed annually - smoking, BP, BG, albuminuria, lipids, FH, height weight and waist cicumference - calculate BMI
- Neuropathy - screen for peripheral and autonomic
10
Q
CKD management/urine microalbuminaemia with diabetes
A
- CKD 3 - Offer atorvastatin
- Offer ACEi - /ARB can have this at any level of CKD
- Add Dapagliflozin (SGLT2) if eGFR 25-75ml/min or more
- If still nor improving renal function, can offer Finerenone
11
Q
Peripheral neuropathy screening
A
Ask about:
* Numbness
* Burning
* Shooting pain
* Tingling
* In hands and feet
* Typically at night
* Relieved by activity
12
Q
Autonomic neuropathy symptoms/screening
A
- Postural hypotension
- Gastroparesis - vomitting, bloating
- Urinary symptoms - hestitancy, reduced frequency, incomplete empyting
- Erectile dysfunction
- Unusual sweating - esp hands and feet
- Impaired hypoglycaemia awareness
13
Q
Managing CVD risk in someone with T2DM
A
- Normal BP targets - stricter 130/80 target if ACR 70mg/mmol or more
- Atorvastatin 20mg - if 84 years and below and QRISk 10% or more, if 85 and above take into account preferences, or if have CKD - aim for more than 40% reduction in non-HDL cholesterol
- Do not routinely offer antiplatelet treatment
14
Q
Lifestyle advice T2DM
A
- High fibre, low glycaemic index carbs (eg fruit, veg, wholegrain, pulses)
- Oily fish
- Low fat dairy products
- Control amounts of high saturated fats, sugary drinks, foods high in salt
- Discourage diabetic marketed foods
- Diabetes UK have good info on diet
- Eat carbohydrate snack before and after alcohol - alcohol can prolong effects of hypoglycaemic treatment
- Need to have regular oral check ups - increased risk peridontitis
- Stop smoking if possible
- Exercise
15
Q
Sick day medication rules
A
- On angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (AIIRAs), diuretics, or nonsteroidal anti-inflammatory drugs (NSAIDs) — stop treatment if there is a risk of dehydration, to reduce the risk of acute kidney injury (AKI).
- On metformin — stop treatment if there is a risk of dehydration, to reduce the risk of lactic acidosis.
- On sulfonylureas — may increase the risk of hypoglycaemia, particularly if dietary intake is reduced.
- On SGLT-2 inhibitors — check for ketones and stop treatment if acutely unwell and/or at risk of dehydration, due to the risk of euglycaemic DKA.
- On GLP-1 receptor agonists — stop treatment if there is a risk of dehydration, to reduce the risk of AKI.
- If on insulin therapy, do not stop treatment.